Last Updated: November 17, 2026

Details for Patent: 7,320,999

« Back to Dashboard


Summary for Patent: 7,320,999
Title:Dimethyl fumarate for the treatment of multiple sclerosis
Abstract:The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Inventor(s):Rajendra Kumar Joshi, Hans-Peter Strebel
Assignee: Biogen International GmbH
Application Number:US10/197,077
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,320,999
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

US Patent 7,320,999 covered the use of dimethyl fumarate as the sole multiple-sclerosis treatment active ingredient, including oral capsules, solid dosage forms, enteric-coated microtablets, and specified 50 mg, 110 mg, and 120 mg quantities. The patent expired on June 9, 2020, eliminating its current blocking effect in the United States. Its commercial importance was tied to Biogen's Tecfidera, an FDA-approved delayed-release dimethyl fumarate product.

US Patent 7,320,999: Scope, Claims, Expiration, Litigation, and Tecfidera Patent Landscape

What does US Patent 7,320,999 protect?

US 7,320,999 protects a method of treating multiple sclerosis by administering a pharmaceutical preparation in which dimethyl fumarate is the only active ingredient directed to treating multiple sclerosis.

The patent does not claim dimethyl fumarate as a compound. It claims a therapeutic use and specific pharmaceutical presentations. The patent is therefore a method-of-treatment patent with dependent claims directed to dosage amounts, capsules, oral administration, solid dosage forms, microtablets, enteric coatings, particle size, carriers, and excipients.

Patent Title Applicant or assignee associated with the patent family Earliest priority date Grant date US expiration
US 7,320,999 Treatment of multiple sclerosis with fumaric acid esters Fumapharm AG and related entities June 9, 1999 January 22, 2008 June 9, 2020

The patent family originated from European and international filings relating to the use of fumaric acid esters, including dimethyl fumarate, in multiple sclerosis. The US patent term ran 20 years from the relevant nonprovisional filing date, subject to any applicable patent-term adjustment. The FDA Orange Book identified the patent as a Tecfidera patent. [1, 2]

What does independent claim 1 require?

Claim 1 has four material limitations:

  1. The treatment must be directed to multiple sclerosis.
  2. The subject must be a patient in need of treatment.
  3. The pharmaceutical preparation must contain an amount effective to treat multiple sclerosis.
  4. Dimethyl fumarate must be the only active ingredient present for treating multiple sclerosis.

The claim does not specify:

  • a particular dose;
  • a particular dosing schedule;
  • oral administration;
  • a capsule;
  • delayed release;
  • enteric coating;
  • microtablets;
  • a particle-size range; or
  • a specific excipient.

A product or treatment could therefore fall within claim 1 without using the formulation details recited in claims 2 through 18, provided the preparation uses dimethyl fumarate as the sole multiple-sclerosis treatment active ingredient and is administered for MS treatment.

The phrase "only active ingredient for the treatment of multiple sclerosis" is narrower than a requirement that dimethyl fumarate be the only pharmacologically active substance in the entire product. The claim language permits carriers, excipients, and potentially other active ingredients directed to unrelated conditions, subject to the facts of a particular product and the applicable claim construction.

How do claims 2 through 18 narrow the patent scope?

The dependent claims create several overlapping protection categories.

Claims Limitation Commercial relevance
2 10 to 300 mg of dimethyl fumarate Broad dose range
3 One or more capsules Capsule presentation
4 At least 50 mg Lower dose threshold
5 At least 110 mg Intermediate threshold
6 At least 120 mg Tecfidera-relevant dose
7 50 mg Exact quantity
8 110 mg Exact quantity
9 120 mg Exact quantity
10 Oral administration Oral MS therapy
11 Solid dosage form Tablets, capsules, and similar forms
12 Microtablets Multiparticulate dosage form
13 Enteric-coated microtablets Protection from gastric release
14 Mean diameter of 0.3 to 2.0 mm, excluding coating Particle-size limitation
15 Mean diameter of 2.0 mm, excluding coating Narrow particle-size limitation
16 Capsule containing 120 mg in enteric-coated microtablets Closest claim to the marketed Tecfidera presentation
17 One or more carriers Composition support
18 One or more excipients Formulation support

Claim 16 is the most commercially specific claim. It requires a capsule containing 120 mg of dimethyl fumarate in enteric-coated microtablets with a mean diameter from 0.3 mm to 2.0 mm, measured without the coating.

The patent does not require the precise Tecfidera label, brand name, capsule color, release profile, or a particular excipient package. A competing product could avoid claim 16 by changing one or more limitations, such as the dose, dosage form, microtablet size, or use of an enteric coating. Before expiration, such design-around strategies would have had to be evaluated against the broader claim 1 and the intermediate claims.

Does US 7,320,999 cover Tecfidera?

Yes. Tecfidera is an oral delayed-release dimethyl fumarate product approved by the FDA for relapsing forms of multiple sclerosis. The initial FDA approval covered 120 mg and 240 mg delayed-release capsules. The 120 mg capsule presentation corresponded closely to claim 16's recitation of 120 mg of dimethyl fumarate in enteric-coated microtablets. [3]

The patent's claims were broader than the marketed product in some respects:

  • Claim 1 was not limited to delayed release.
  • Claim 1 was not limited to capsules.
  • Claim 1 did not require 120 mg.
  • Claims 2 and 4 through 9 covered multiple quantities.
  • Claims 10 and 11 covered oral and solid dosage forms without requiring microtablets.

Tecfidera's 240 mg maintenance dose also fell within claim 2's 10 to 300 mg range and claim 4's "at least 50 mg" limitation. The 120 mg starter dose was expressly recited in claims 6, 8, 9, and 16.

When did US 7,320,999 lose exclusivity?

The patent expired on June 9, 2020. After that date, the patent could no longer block an ANDA applicant or commercial launch based on the US patent right.

The key US exclusivity timeline was:

Date Event
June 9, 1999 Earliest priority date for the patent family
January 22, 2008 US 7,320,999 issued
March 27, 2013 FDA approved Tecfidera
March 27, 2018 Standard five-year new chemical entity exclusivity period ended
June 9, 2020 US 7,320,999 patent term ended
2020 onward Generic dimethyl fumarate entry became legally possible, subject to other listed patents and regulatory requirements

FDA regulatory exclusivity and patent exclusivity were separate. The five-year NCE period prevented submission or approval of certain ANDAs during the statutory period, while the patent restricted conduct covered by the patent claims. [3, 4]

What was the Paragraph IV litigation involving US 7,320,999?

Biogen sued Mylan after Mylan filed an ANDA seeking approval of generic delayed-release dimethyl fumarate capsules. The litigation was brought in the US District Court for the District of Delaware as Biogen International GmbH v. Mylan Pharmaceuticals Inc.

Mylan's Paragraph IV position challenged the patent's validity and enforceability and asserted that its proposed product would not infringe the patent. The central validity issue was obviousness.

The district court found the asserted claims invalid for obviousness. Biogen appealed. The US Court of Appeals for the Federal Circuit later reversed the district court's obviousness determination, holding that the trial court had not established the required motivation to combine the prior art with a reasonable expectation of success. The Federal Circuit decision preserved the patent's validity during the appellate dispute, although the patent had already reached its June 9, 2020 expiration date by the time generic entry became commercially relevant. [5, 6]

The litigation had several practical consequences:

  • It delayed certainty regarding the enforceability of the patent.
  • It created potential damages exposure for an at-risk launch.
  • It tested whether prior art involving fumarate compounds and MS treatment made the claimed use obvious.
  • It did not create a continuing patent barrier after June 9, 2020.

What prior art created validity risk for the patent?

The principal technical validity issue concerned whether the use of dimethyl fumarate for multiple sclerosis was obvious in view of earlier fumarate disclosures.

Relevant prior-art themes included:

  • fumaric acid ester treatment for dermatological conditions;
  • use of fumarate mixtures containing dimethyl fumarate;
  • immunomodulatory effects associated with fumarate compounds;
  • disclosures involving neurological or inflammatory disease;
  • clinical and mechanistic information available before the patent's priority date.

The patent's commercial success did not by itself resolve validity. The litigation focused on whether a skilled person would have selected dimethyl fumarate for MS treatment and expected it to work based on the prior art. The Federal Circuit placed weight on the absence of a sufficient showing that the skilled person would have had a reasonable expectation of success. [5]

The patent's strength was uneven across claim categories:

Claim category Relative position before expiration Main vulnerability
Broad MS treatment with DMF Commercially powerful but validity-sensitive Obviousness and claim construction
Dose claims Narrower and easier to map to a product Potential obviousness or lack of criticality
Oral and solid dosage claims Broad formulation coverage Limited technical distinction
Enteric-coated microtablets More technically specific Prior-art formulation disclosures
120 mg capsule with microtablets Strong product-read-on potential Particle size and formulation design-around

What other patents covered Tecfidera?

US 7,320,999 was the foundational use patent, but Biogen's broader Tecfidera patent strategy included later patents directed to formulations, delayed release, dosage forms, and related pharmaceutical compositions.

Representative later Orange Book-listed patent families included:

Patent General subject matter Reported expiration period
US 8,399,514 Dimethyl fumarate pharmaceutical formulation or dosage-form technology 2028
US 8,759,393 Dimethyl fumarate formulation and release technology 2028
US 9,090,574 Related Tecfidera formulation or method claims 2020 or later, depending on listed patent and term adjustments
US 9,226,917 Later dimethyl fumarate formulation protection 2028
US 9,295,657 Related pharmaceutical composition or formulation protection 2028
US 9,889,097 Later formulation and product protection 2028

The exact Orange Book status of each patent depended on the reference-listed drug, patent listing, statutory disclaimer, term adjustment, and litigation history. Later patents were more important to generic-entry analysis after the expiration of US 7,320,999 because they could target the commercial product's delayed-release formulation rather than the underlying MS use alone. [2]

What is the Orange Book status of US 7,320,999?

The FDA Orange Book listed US 7,320,999 for Tecfidera during the period when the patent was in force. Its listing identified patent protection associated with the drug product and was relevant to ANDA certifications.

After expiration, the patent ceased to provide a live US patent barrier. An Orange Book listing does not extend patent term. It also does not independently establish infringement. The listing connects the patent to the approved drug for regulatory certification purposes. [2]

The patent should therefore be treated as:

  • historically listed;
  • expired as of June 9, 2020;
  • no longer a current injunction basis;
  • no longer a barrier to approval or launch based on its own claims.

Which companies challenged or entered the dimethyl fumarate market?

Mylan was the most prominent early challenger in the litigation involving US 7,320,999. Other generic manufacturers pursued or obtained approval for dimethyl fumarate delayed-release capsules after the relevant patent and exclusivity barriers declined.

The competitive set included generic manufacturers such as:

  • Mylan, later part of Viatris;
  • Zydus;
  • Dr. Reddy's Laboratories;
  • Amneal;
  • Glenmark;
  • other ANDA sponsors depending on product strength and approval timing.

Generic entry depended on more than the expiration of US 7,320,999. Applicants also had to address:

  • the FDA's ANDA requirements;
  • Orange Book-listed later patents;
  • Paragraph IV certification or section viii statement strategy;
  • 180-day generic exclusivity, where applicable;
  • bioequivalence to the reference listed drug;
  • delayed-release performance;
  • capsule strength and labeling.

Is there biosimilar risk for Tecfidera?

No. Tecfidera is a small-molecule drug, not a biologic. It is subject to the ANDA generic pathway rather than the biosimilar pathway under the Public Health Service Act.

The relevant competitive threat is generic dimethyl fumarate, not a biosimilar. FDA approval depends primarily on pharmaceutical equivalence and bioequivalence to the reference product, including the delayed-release dosage form.

What formulation and manufacturing barriers remain after patent expiry?

The expired patent's enteric-coated microtablet claims described one formulation architecture, but manufacturing complexity can still affect generic competition.

Important technical barriers include:

  • uniform dimethyl fumarate loading;
  • protection from premature gastric release;
  • enteric-coating uniformity;
  • microtablet diameter control;
  • capsule filling accuracy;
  • stability under humidity and temperature stress;
  • dissolution matching across strengths;
  • reproducible delayed-release performance.

These are regulatory and manufacturing barriers, not substitutes for an expired patent. A manufacturer can face development and approval costs even when no enforceable patent blocks entry. Later formulation patents may also create risk if the generic product copies protected features of the reference product.

How strong was the commercial value of US 7,320,999?

The patent was commercially important because it covered the therapeutic use underlying Tecfidera, a major MS product. Biogen reported Tecfidera revenue of approximately $4.4 billion in 2019, before generic competition materially affected the product's commercial position. [7]

Its commercial strength came from the combination of:

  • a broad MS treatment claim;
  • direct coverage of dimethyl fumarate monotherapy;
  • dose claims corresponding to marketed strengths;
  • capsule and oral dosage claims;
  • a product-specific 120 mg enteric-coated microtablet claim;
  • FDA approval of Tecfidera during the patent term.

Its economic weakness was the fixed patent expiration date. Once the patent expired, the broad claim no longer protected the market from generic products, even though later formulation patents could continue to affect entry strategy.

What generic launch scenarios existed after expiration?

Three entry scenarios were commercially relevant:

  1. Launch after patent expiration.
    A generic could launch after June 9, 2020, assuming regulatory approval and no enforceable later patent prevented launch.

  2. At-risk launch before final litigation resolution.
    An ANDA sponsor could launch before final resolution, accepting potential damages and injunction risk if the patent were upheld and infringement were found.

  3. Delayed or limited launch because of later patents.
    A company could obtain approval but delay commercial entry, launch with a formulation design-around, or contest later formulation patents.

Because US 7,320,999 expired in 2020, its own claim scope no longer determines current launch timing. Current analysis must focus on remaining Orange Book patents, settlement terms, FDA approval status, and product-specific infringement exposure.

Did Biogen settle with generic challengers?

The public record around Tecfidera included patent litigation, generic challenges, and commercial-entry negotiations. Settlement analysis must be performed challenger by challenger because agreements can differ in launch date, licensing rights, authorized-generic provisions, and treatment of later patents.

US 7,320,999 itself cannot support a current settlement-based launch restriction after expiration. Any continuing settlement impact would have to arise from other patents, contractual terms, or separate regulatory arrangements.

Key Takeaways

  • US 7,320,999 was a method-of-treatment patent for using dimethyl fumarate as the only MS treatment active ingredient.
  • Claim 1 was broad because it did not require a specific dose, route, capsule, or delayed-release formulation.
  • Claims 2 through 18 added dose, capsule, oral, solid dosage, microtablet, enteric-coating, particle-size, carrier, and excipient limitations.
  • Claim 16 most closely tracked Tecfidera's 120 mg enteric-coated microtablet capsule.
  • The patent expired on June 9, 2020.
  • Biogen prevailed at the Federal Circuit on the contested obviousness issue after the district court had found the patent invalid.
  • Tecfidera is subject to generic, not biosimilar, competition.
  • Later formulation patents, rather than US 7,320,999, became the primary patent issue for post-2020 generic entry.
  • The patent had substantial historical revenue significance because Tecfidera generated approximately $4.4 billion in 2019 sales.

FAQs

Can a generic company practice claim 1 after June 9, 2020?

Yes. The patent expiration removes the US patent restriction created by claim 1, subject to other valid patents and regulatory requirements.

Does US 7,320,999 cover fumaric acid esters other than dimethyl fumarate?

The asserted claims provided here specifically require dimethyl fumarate. They do not, on their face, cover other fumaric acid esters.

Does the patent require treatment with exactly 120 mg?

No. Claim 1 has no dose limitation. Claims 2 and 4 through 9 introduce dose limitations, and claim 16 specifically recites 120 mg.

Could a tablet avoid the patent's capsule claims?

A tablet could avoid claims requiring a capsule, including claim 3 and claim 16. It could still implicate claim 1, claim 2, claim 4, claim 7, claim 8, claim 9, claim 10, claim 11, or other claims depending on its dose and use.

Is a product with another active ingredient automatically outside claim 1?

No. Claim 1 excludes another active ingredient for treating multiple sclerosis. It does not necessarily exclude every other pharmacologically active substance directed to an unrelated condition.

References

  1. United States Patent and Trademark Office. (2008). US Patent No. 7,320,999: Treatment of multiple sclerosis with fumaric acid esters.

  2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

  3. U.S. Food and Drug Administration. (2013). Tecfidera approval package and prescribing information.

  4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. ยง 355.

  5. Biogen International GmbH v. Mylan Pharmaceuticals Inc., Federal Circuit appellate decision concerning US Patent No. 7,320,999.

  6. Biogen International GmbH v. Mylan Pharmaceuticals Inc., U.S. District Court for the District of Delaware litigation concerning validity and infringement of US Patent No. 7,320,999.

  7. Biogen Inc. (2020). Annual report on Form 10-K for fiscal year ended December 31, 2019.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,320,999

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,320,999

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany198 53 487Nov 19, 1998

International Family Members for US Patent 7,320,999

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1131065 ⤷  Start Trial C300675 Netherlands ⤷  Start Trial
European Patent Office 1131065 ⤷  Start Trial CA 2014 00036 Denmark ⤷  Start Trial
European Patent Office 1131065 ⤷  Start Trial PA2014023 Lithuania ⤷  Start Trial
European Patent Office 1131065 ⤷  Start Trial 92488 Luxembourg ⤷  Start Trial
European Patent Office 1131065 ⤷  Start Trial 39/2014 Austria ⤷  Start Trial
European Patent Office 1131065 ⤷  Start Trial 1490039-3 Sweden ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.